Literature DB >> 32015868

Treatment of Chronic HCV Infection in Patients With Thalassemia.

Halim Bou Daher1, Ala I Sharara1.   

Abstract

Entities:  

Year:  2020        PMID： 32015868      PMCID： PMC6988433          DOI： 10.1002/cld.853

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  21 in total

1.  Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major.

Authors:  Chi Kong Li; Paul K S Chan; Siu Cheung Ling; Shau Yin Ha
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

2.  Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon alpha-2b and ribavirin.

Authors:  Averell H Sherker; Madeleine Senosier; Delia Kermack
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

3.  Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia.

Authors:  Ala I Sharara; Luma Basma O Rustom; Majd Marrache; Hussein H Rimmani; Halim Bou Daher; Suzanne Koussa; Ali Taher
Journal:  Am J Hematol       Date:  2018-11-29       Impact factor: 10.047

4.  Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

Authors:  A Mangia; R Sarli; R Gamberini; A Piga; G Cenderello; V Piazzolla; R Santoro; V Caruso; A Quarta; R Ganga; M Copetti; G Forni
Journal:  Aliment Pharmacol Ther       Date:  2017-06-29       Impact factor: 8.171

5.  Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.

Authors:  Adlette Inati; Ali Taher; Sandy Ghorra; Suzanne Koussa; Marwan Taha; Elie Aoun; Ala I Sharara
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

6.  Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia.

Authors:  V Di Marco; O Lo Iacono; M Capra; S Grutta; C Ciaccio; C Gerardi; A Maggio; D Renda; P Almasio; R Pisa
Journal:  Gut       Date:  1993       Impact factor: 23.059

Review 7.  Thalassaemia.

Authors:  Douglas R Higgs; James Douglas Engel; George Stamatoyannopoulos
Journal:  Lancet       Date:  2011-09-09       Impact factor: 79.321

8.  Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.

Authors:  Christophe Hézode; Massimo Colombo; Marc Bourlière; Ulrich Spengler; Ziv Ben-Ari; Simone I Strasser; William M Lee; Leslie Morgan; Jingjun Qiu; Peggy Hwang; Michael Robertson; Bach-Yen Nguyen; Eliav Barr; Janice Wahl; Barbara Haber; Robert Chase; Rohit Talwani; Vito Di Marco
Journal:  Hepatology       Date:  2017-07-20       Impact factor: 17.298

9.  Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.

Authors:  Aabha Nagral; Ajay Jhaveri; Smita Sawant; Nirzar Samir Parikh; Nishtha Nagral; Rashid Merchant; Mihir Gandhi
Journal:  Indian J Pediatr       Date:  2018-08-10       Impact factor: 5.319

10.  Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major.

Authors:  Rajiv Mehta; Mayank Kabrawala; Subhash Nandwani; Pankaj Desai; Vishwa Bhayani; Sanjay Patel; Viral Parekh
Journal:  J Clin Exp Hepatol       Date:  2017-06-23
View more
  2 in total

1.  Revolution in the diagnosis and management of hepatitis C virus infection in current era.

Authors:  Farina M Hanif; Zain Majid; Nasir Hassan Luck; Abbas Ali Tasneem; Syed Muddasir Laeeq; Muhammed Mubarak
Journal:  World J Hepatol       Date:  2022-04-27

Review 2.  Hepatitis C virus: A critical approach to who really needs treatment.

Authors:  Elias Kouroumalis; Argyro Voumvouraki
Journal:  World J Hepatol       Date:  2022-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.